[Chronic inflammation as promotor and treatment target in benign prostate hyperplasia (BPH) and in prostate cancer].
Kramer
G
G
Klinik für Urologie, Medizinische Universität, Währinger Gürtel 18-20, A-1090, Wien, Osterreich. gero.kramer@meduniwien.ac.at
Mitteregger
D
D
Maj-Hes
A
A
Sevchenco
S
S
Brozek
W
W
D001323:Autoantibodies / Q000378:metabolism; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002471:Cell Transformation, Neoplastic / Q000276:immunology / Q000473:pathology*; D002908:Chronic Disease; D016207:Cytokines / Q000378:metabolism; D018450:Disease Progression; D006801:Humans; D008297:Male; D011379:Prognosis; D011467:Prostate / Q000276:immunology / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000276:immunology / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000276:immunology / Q000473:pathology*; D011472:Prostatitis / Q000276:immunology / Q000473:pathology*
D001323:Autoantibodies; D016207:Cytokines